Guangzhou Sinogen Pharmaceutical was selected into the 2022 Guangzhou Future Unicorn Innovative Enterprise List.

Sinogen Pharmaceutical, which has developed the first-in-class tumor-targeting drug based on amino acid metabolism, its oncolytic bacteria core product SGN1® (SalMet-Vec ®) is carrying out Phase I/IIa registered clinical trials of intravenous and intratumoral drug delivery for broad-spectrum solid tumors in the United States and Taiwan, China, China.
This "Future Unicorn" Innovative Enterprise Award is an affirmation of the development stage and enterprise value of  Sinogen Pharmaceutical, and will also encourage the company to continue to make efforts towards the goal of a true “Unicorn” enterprise.

Introduction of  Guangzhou "Unicorn" Innovative Enterprise List

Guangzhou "Unicorn" Innovative Enterprise List is an authoritative list under the guidance of Guangzhou Municipal Bureau of Science and Technology and sponsored by Guangzhou Association of Science and Technology Innovation Enterprises. The selection of innovative enterprises with strong innovation, fast growth and great development potential in Guangzhou through enterprise application, expert evaluation and other procedures is an important vane for the development of Guangzhou's new economy.
The "Future Unicorn" Innovative Enterprise Award is set to explore innovative enterprises with the potential to become "Unicorn", targeting enterprises with institutional equity investment and market valuation between 100 million and 1 billion dollars.